AC Immune SA expected to post a loss of 17 rappen a share - Earnings Preview

AC Immune SA

01/08/2025 14:20

AC Immune SA ACIU.OQ ACIU.O is expected to  show a rise in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The Lausanne Vaud-based  company is expected to report a 188.2% increase in revenue to CHF1.98 million from CHF687 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for AC Immune SA is for a loss of 17 rappen per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for AC Immune SA is $9.00, about 76% above its last closing price of $2.16

Previous quarterly performance (using preferred earnings measure in Swiss francs). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.20
-0.21
-0.19
Beat
7.3
Dec. 31 2025
-0.17
-0.19
-0.16
Beat
14.6
Sep. 30 2024
-0.19
-0.20
0.05
Beat
125.5‚Äč
Jun. 30 2024
0.35
0.27
-0.23
Missed
-185.4
‚Äč‚ÄčMar. 31 2024
-0.13
-0.14
-0.18
Missed
-33.2
Dec. 31 2023
-0.06
-0.11
-0.05
Beat
55.9‚Äč
Sep. 30 2023
-0.07
0.03
-0.18
Missed
-801.2
Jun. 30 2023
-0.19
-0.20
-0.20
Met
-1.4

This summary was machine generated August 1 at 13:20 GMT.  All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)